Connecticut, USA-based Alexion Pharmaceuticals (Nasdaq: ALXN) has announced a wide-ranging restructuring plan in which it will cut a fifth of its workforce, consolidate manufacturing facilities, axe funding for certain research programs and relocate its headquarters to Boston, Massachusetts.
As previously announced, funding for the ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) programs will be cut off, and partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma terminated.
Multiple Alexion manufacturing sites will be shuttered, including the Alexion Rhode Island facility and other regional and country-based offices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze